The first patient has joined a Phase 3 clinical trial assessing the safety and efficacy of Descartes-08, an investigational cell therapy for myasthenia gravis (MG) being developed by Cartesian Therapeutics. Called AURORA (NCT06799247), the trial is expected to enroll 100 adults with generalized MG (gMG), a more…
News
Mike Stabile holds his grandson, Alex Stabile, while in between myasthenia gravis flare-ups. (Courtesy of Mike Stabile) This is Mike Stabile’s story: There are no physical signs that I have myasthenia gravis (MG). My last flare-up ended in July, 11 months ago. Previous flare-ups would last two to…
Organizations are holding events and activities in June in recognition of Myasthenia Gravis Awareness Month, an annual observance that aims to raise awareness of myasthenia gravis (MG), an autoimmune disease that affects 90,000-100,000 people in the U.S. alone. “Throughout June, Myasthenia Gravis News is recognizing awareness month with a…
Retha De Wet enjoyed three happy years in remission from myasthenia gravis, during which time she gave birth to her daughter. But her symptoms have recently reemerged. (Courtesy of Retha De Wet) This is Retha De Wet’s story: I have always wanted to be a mother. I’ve always wanted…
Jasmine Nathan was diagnosed with generalized myasthenia gravis with thymoma in 2018, but now has her gMG fully managed. (Photo courtesy of Jasmine Nathan) This is Jasmine Nathan’s story: It was the summer of 2018 in Chicago. I was trying to balance everything. I had a husband, a stepson,…
Using tears to test for self-reactive antibodies to help diagnose ocular myasthenia gravis (OMG) is more accurate than using blood samples, according to a study that found nearly all patients who tested negative for these antibodies in the blood had a positive result in tears. “Tear-based testing offers a…
Remegen’s telitacicept has been approved in China as an add-on treatment for adults with generalized myasthenia gravis (gMG) who are positive for antibodies targeting the acetylcholine receptor (AChR) — that’s approximately 80% of all gMG patients, per the company. The decision, by the country’s National Medical Products Administration…
A rare form of myasthenia gravis that manifests in childhood and adolescence called juvenile myasthenia gravis (JMG) affects roughly 30 out of every 1 million children in the U.S., and may be more common than previously thought, a study estimates. The study also found that JMG is more common…
Vyvgart (efgartigimod alfa-fcab) may be safer and more effective than intravenous immunoglobulin (IVIG) therapy in elderly people with generalized myasthenia gravis (gMG), a study shows. In elderly Chinese patients with gMG who were positive for antibodies targeting the acetylcholine receptor (AChR), Vyvgart eased symptoms after four and…
Enrollment is open in an investigator-initiated clinical trial to evaluate cell therapy NKX019 in people with myasthenia gravis (MG). Nkarta, the therapy’s developer, made the announcement in a company press release. Researchers at the University of California, Irvine, and the University of Kansas Medical Center are leading the…
Recent Posts
- Key early results coming next year in global myasthenia gravis trial
- Guest Voice: My MG diagnosis led me to become a patient researcher
- Not asking anymore why I developed myasthenia gravis
- Global trial validates self-administered treatment for myasthenia gravis
- Reflecting on decades of rich history that led to our modern MG treatments